Stock Watch: Regeneron Battles On Two Fronts

Competition Appears From All Sides In Two Big Indications

As it navigates product transition in ophthalmology against biosimilar and branded rivals, Regeneron seems to have a simpler challenge in another major therapeutic area.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

When Regeneron Pharmaceuticals, Inc.* released its second-quarter results, I was anticipating more insight and specifics about the transition of its leading brand Eylea (aflibercept 2mg) – for eye conditions like age-related macular degeneration (AMD) – to the higher dose (HD) version (aflibercept 8mg). Additionally, I was keen to understand how the brand is competing with biosimilars and Roche Holding AG’s Vabysmo (faricimab).

The situation is complicated and the sales of Eylea do not tell yet the whole story of how the combatants...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Stock Watch

More from Business

Venture Funding Plummets In Q2 As Mega-Rounds Falter

 
• By 

Evaluate’s second quarter data show that VC rounds of $100m or more totaled $2.36bn, down from $5.25bn in Q2 of 2024. Overall, the Q2 total dropped year-over-year to $4.92bn from $7.95bn.

Stock Watch: US CAR-T And Vaccine Actions: Net Negative For Access

 
• By 

Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By 

Coartem Baby to be rolled out in eight African countries in the autumn.